Patrick W. Serruys教授

　　我第一次参加CIT是在2002年左右,在阜外医院做示教演示。那时患者不多,治疗也仅为支架置入等简单手术。到了2009年,我不再示教,因为中国本土治疗的质量大大提高,有能力做复杂手术的年轻医生比比皆是。

　　CIT每年吸引数百位来自全球的心脏科专家参会。我想其中一个原因是中国从未像今天这样对外界真正敞开大门。并且中国介入心脏病学之父高润霖教授一直致力于提高中国在该领域的发展。来中国后,我发现这里的患者数量和诊疗技术都引人注目。中国心脏病诊疗策略一般由患者选择,这与欧美国家普遍遵循指南非常不同。我很好奇这些患者行经皮冠脉介入之后的长期预后会怎样。

　　过去几年中国在介入心脏病学领域的进展让我叹服,例如随机临床试验产生了高质量数据、原创科学研究与诊疗技术影响世界。我认为未来几年中国在该领域的发展将是爆发式的,令人难以想象。作为Euro Intervention的姐妹刊,现在我们有了Asia Intervention,中国介入心脏病学将会吸引更多国际关注。

　　The first time I came to CIT was around 2002, when I made live demonstrations in FuwaiHospital. There were not many patients then and only simple treatments were carried out, such as stenting. Around 2009, I stopped doing live demonstrations because the treatments were of high quality and there were so many young people being able to handle difficult procedures.

　　CIT attracts hundreds of cardiologists from all over the world every year. I think one reason is that China was not really open to the world outside before. Furthermore, Dr. Runlin Gao, the father of interventional cardiology in China, has been making great effort in promoting this filed in China. After I came to this country, I realized that the technology and the number of patients were very phenomenal. The approaches of treatment in China, which are mainly decided by the patients themselves, differ a lot from that in western countries, where everything follows the guideline. I am very curious to see the long-term follow-up outcomes of these patients undertaking PCI.

　　During the last few years, I am amazed by the progress of interventional cardiology in this country, such as the high quality of data generated from clinical trials, the originality of science and techniques of international impact. I think in the coming years, China’ s development in this field will be explosive, which are just out of my imagination.

　　Now we have the Asia Intervention journal, parallel to the Euro Intervention, which once again attracts the world's attention to the intervention cardiology in China.